Get the Stockscreener App
76.60
0.49%
-0.38
Forte Biosciences Inc stock is traded at $76.60, with a volume of 794.04K.
It is down -0.49% in the last 24 hours and up +260.47% over the past month.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
See More
Previous Close:
$76.98
Open:
$76.62
24h Volume:
794.04K
Relative Volume:
1.04
Market Cap:
$1.57B
Revenue:
-
Net Income/Loss:
$-75.86M
P/E Ratio:
-15.00
EPS:
-5.1069
Net Cash Flow:
$-59.39M
1W Performance:
+39.83%
1M Performance:
+260.47%
6M Performance:
+161.70%
1Y Performance:
+667.54%
1-Day Range:
$76.54
$76.74
1-Week Range:
$76.38
$77.20
52-Week Range:
$9.10
$77.20
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
76.60 | 1.57B | 0 | -75.86M | -59.39M | -5.1069 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Evercore ISI | Outperform |
| Aug-18-25 | Initiated | Guggenheim | Buy |
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Netherlands: argenx to acquire Forte Biosciences for US$2.2bn - Investors in Healthcare
argenx signs agreement to buy Forte Biosciences for $2.2bn - Yahoo Finance
Biotech Growth makes 14-times return on Forte Biosciences accepting $2.2bn bid from Argenx SE - QuotedData
Barclays cuts Forte Biosciences stock rating on acquisition terms By Investing.com - Investing.com Canada
Barclays cuts Forte Biosciences stock rating on acquisition terms - Investing.com
Forte Biosciences (FBRX) Stock Looks Stretched On Book Value Yet Strong On Pipeline Hope - simplywall.st
Biotech Growth Trust Notes $2.2 Billion Acquisition Of Forte Biosciences - DirectorsTalk Interviews
argenx acquires Forte Biosciences for FB102 - BioXconomy
Forte Biosciences Inc (FBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Why Did AAPL, FBRX, RTX Stocks Surge To 52-Week Highs Today? - TradingView
Dallas biopharmaceutical company to be acquired for over $2B - Dallas News
Why is Forte Biosciences stock surging nearly 40% today? By Investing.com - Investing.com UK
Argenx enters biotech buyer class with $2.2B Forte takeout - BioCentury
argenx (FBRX counterparty) plans full-share tender offer for Forte Biosciences - Stock Titan
Argenx’s $2B Forte Bio Acquisition Brings Autoimmune Playbook to Prevalent Disorders - MedCity News
The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today - Barchart.com
Firm Advises Forte Biosciences on $2.2 Billion Acquisition by argenx - Wilson Sonsini
Argenx to acquire Forte Biosciences for $2.2 billion - Drug Discovery News
Forte Biosciences agrees to $2.2 billion buyout - The Business Journals
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Forte Biosciences, Inc. (NASDAQ: FBRX) - Morningstar
Argenx to Acquire Forte Biosciences for $2.2 Billion, Bolstering Immunology Pipeline with Promising Anti-CD122 Antibody - finance.biggo.com
Shareholder Alert: Ademi LLP investigates whether Forte Biosciences, Inc. is obtaining a Fair Price for Public Shareholders - Morningstar
Forte: 'Hold' On Positive FB102 Vitiligo Treatment Data And argenx Acquisition For $2.2 Billion - Seeking Alpha
Argenx Buys Forte Biosciences for $2.2B to Boost Pipeline - Briefs Finance
Stocks making the biggest moves midday: ASML, SK Hynix, SAP, Forte Bio, Brown-Forman & more - CNBC
Argenx to buy Forte Biosciences for about $2.2 billion - 95.7 KELO-FM
FBRX Stock Extends Surge As Barclays Lifts Target On FB102 Momentum - StocksToTrade
Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B - Proactive financial news
Argenx expands immune pipeline in $2.2B cash acquisition of Forte - BioWorld News
Argenx (ARGX) to Acquire Forte Biosciences for $2.2 Billion - GuruFocus
argenx To Acquire Forte Biosciences: What Investors Should Know (NASDAQ:ARGX) - Seeking Alpha
argenx Expands Immunology Pipeline with Forte Biosciences Acquis - GuruFocus
Forte Biosciences Inc (FBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
argenx to Acquire Forte Biosciences for $2.2 Billion, Adding Anti-CD122 Antibody FB102 - BioPharm International
Forte Biosciences Surges on $2.2 Billion Cash Buyout Deal - Quiver Quantitative
argenx boosts immuno expertise with buy of Forte Biosciences - The Pharma Letter
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks M - Benzinga
Argenx to acquire Forte Biosciences for $2.2B - Axios
argenx to Acquire Forte Biosciences for $77.00 Per Share in Cash Deal - Kalkine Media
argenx SE (ARGX) to Acquire Forte Biosciences (FBRX) for $2.2B - GuruFocus
argenx to Acquire Forte Biosciences for $2.2 Billion - Contract Pharma
FBRX Stock Extends Rally As Barclays Lifts Biotech Hopes - StocksToTrade
Argenx (ARGX.US) makes a bold $2.2 billion acquisition of Forte Biosciences (FBRX.US) at a 40% premium, strengthening its immunology drug portfolio. - Bitget
argenx Acquires Forte Biosciences for $2.2 Billion - Pharmaceutical Executive
FBRX Stock Surges As Barclays Backs FB102 Breakthrough - timothysykes.com
argenx to buy Forte Bio for $2.2B in immunology push - FirstWord Pharma
Freshfields-Led Drug Co. To Buy Forte Biosciences For $2.2B - Law360
TD Cowen downgrades Forte Biosciences stock rating on Argenx deal By Investing.com - Investing.com Canada
TD Cowen downgrades Forte Biosciences stock rating on Argenx deal - Investing.com
argenx to Acquire Forte Biosciences in $2.2 Billion Deal to Expand Autoimmune Pipeline - citybiz
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy - BioSpace
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Forte Biosciences Inc Stock (FBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '26 |
Option Exercise |
0.00 |
375 |
0 |
41,895 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Dec 30 '25 |
Buy |
26.33 |
9,680 |
254,833 |
41,520 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,974 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
82,190 |
2.44%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):